BioSpace News Archive

Trial results showed that tolvaptan showed greater reduction on the primary endpoint, the rate of change in estimated glomerular filtration rate (eGFR) compared to placebo.

- Late-breaking presentation at the 2017 American College of Rheumatology/Association of Rheumatology Health Professionals Annual Meeting (ACR/ARHP) provides data on cartilage thickness in patients with knee osteoarthritis - Additional data at ACR/ARHP highlights the momentum of the company’s clinical programs in systemic lupus erythematosus (SLE), osteoarthritis (OA), rheumatoid arthritis (RA) and fibrotic diseases [04-Novemb

These studies, along with six others that were conducted in partnership with major academic institutions who surveyed the CreakyJoints membership or analyzed data from the ArthritisPower research registry, developed by CreakyJoints, will be presented during the 2017 ACR/AHRP Annual Meeting in San Diego, California, November 4-8, 2017.

The Race features a 5K run and a 1-mile walk in downtown Washington, DC along historical Pennsylvania Avenue, NW, on Sunday morning, Nov. 5.

The Quark trial was a global multicenter study that included 341 subjects of age 45 or greater and at risk for AKI undergoing cardiac surgery, randomized in a 1:1 ratio to QPI-1002 or placebo.

- 12 of 15 (80%) patients completed the study and achieved the primary endpoint of at least a two-point reduction in the IgG4-RD Responder Index on Day 169 - - Eight patients achieved remission (IgG4-RD RI of zero) - - XmAb5871 well tolerated in patients with active IgG4-RD - [04-November-2017] MONROVIA, Calif., Nov. 4, 2017 /PRNewsw